Comparison Of The Safety And Effectiveness Of Intravenous Metoprolol Versus Cedilanid In The Management Of Rapid Ventricular Rate In Atrial Fibrillation

Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia in clinical practice. Some episodes of AF are associated with severe symptoms, hemodynamic impairment and serious complic ations. The first aim for those patients with great heart rate is to decreace the high rate.Digitslis had been the drug of first choice for ventricular rate control in patients with AF,but when sympathetic tone is increased or in acute settings,it is often unsuccessful. However, because of the positive inotropic action, it remains the treatment of choice for ventricular rate control in patients with AF and chronic heart fuilure(CHF). Several studies now clearly show thatβ-blockers are very effective in controlling the ventricular rate at rest and during exercise. Given the conclusions of these studies,β-blockers has been considered as the first-line agents in the management of patients with rapid atrial fibrillation. But most studies of rate control have excludeded patients with heart failure,and Thus,the risk-benefit relationship ofβ–blockers for rate control in patients with heart failure (expecially intravenousing in acute episode) is still unknown。Some studies seem to showβ–blockers may be a logical treatment of choice in this clinical setting. But relative studies are very few. The observation and assessment aboutβ-blockers are not adequate now. So the safety and effectiveness for it to treat Rapid atrial fibrillation remains unknown .Objective: To compare the safety and effectiveness of intravenous (IV) metoprolol versus cedilanid in the management of rapid ventricular...